Implementation of an intensified antibiotic stewardship programme targeting third-generation cephalosporin and fluoroquinolone use in an emergency medicine department

Johannes P Borde,¹ Winfried V Kern,¹ Martin Hug,² Michaela Steib-Bauert,¹ Katja de With,¹,³ Hans-Jörg Busch,¹,⁴ Klaus Kaier⁵

ABSTRACT

Introduction Early initiation of antimicrobial treatment for acute infection is an important task in the emergency department (ED) with a likely impact on the hospital-wide antibiotic use pattern. We implemented an antibiotic stewardship (ABS) programme focused on non-trauma emergency patients at a large university hospital centre targeting broad-spectrum cephalosporin and fluoroquinolone use.

Methods Guidelines and focused discussion groups emphasised reduced prescription of third-generation cephalosporins and fluoroquinolones and encouraged penicillins. Antibiotic consumption expressed as monthly drug density in WHO-Anatomical Therapeutic Chemical defined and locally recommended daily doses (DDD and RDD) per 100 patient days was analysed before (January 2008 to October 2011) and after starting the intervention (January 2012 to October 2013). We performed a before-and-after uncontrolled interventional study using interrupted time-series (ITS) analysis in one ED to investigate ABS intervention-related effects in a quasiexperimental research setting.

Results The mean monthly total antibiotic use density declined from 111 RDD (138 DDD) per 100 patient days before the intervention to 86 RDD (128 DDD) per 100 patient days after starting the intervention. Among the different antibacterial drug classes, the consumption of third-generation cephalosporins showed the largest reduction and dropped significantly by −68% between preintervention and postintervention periods. Using the RDD dataset, ITS confirmed a highly significant postintervention change in level of third-generation cephalosporins (−15.2, 95% CI (−24.08 to −6.311)) and a corresponding increase in the use of aminopenicillin/betalactamase inhibitor formulations (+6.6, 95% CI (4.169 to 9.069)). The drug use densities for fluoroquinolones and for overall antibiotics declined, however, the postinterventional level changes missed statistical significance—overall (95% CI (−39.99 to 0.466)), fluoroquinolones 95% CI (−11.72 to 4.333).

Conclusions An intensified ABS programme using non-restrictive tools targeting third-generation cephalosporin and fluoroquinolone use in the setting of a large academic hospital emergency medicine department is feasible and effective. The intervention may serve as a model for other emergency medicine departments at hospitals with a similar structure and baseline situation.

INTRODUCTION

Increasing bacterial resistance is a major threat to patients and healthcare systems worldwide. The causes of antibiotic resistance are complex, but include heavy use of antibiotics, both in humans and animals.¹ An essential component in the strategies to reduce antimicrobial resistance is to limit overaggressive use of antibiotics in the hospital and primary care setting.²,³ Earlier studies have demonstrated that a reduction in aminoglycoside prescription is linked to a decreasing incidence of Gram-negative resistant bacteria.⁴,⁵ Similar findings are reported for the restriction of third-generation cephalosporins⁶,⁷ and fluoroquinolones.⁷,⁸ A reduction of infections due to Clostridium...
**difficile**, methicillin-resistant *Staphylococcus aureus* infections and Gram-negative bacteria producing extended-spectrum beta-lactamases (ESBL) could be achieved by effective antibiotic stewardship (ABS) interventions. Reducing the antibacterial drug use density for the inpatient service is challenging, but has been successfully demonstrated in several interventional studies over the last 20 years. The long-established Anglosaxon model of large interdisciplinary emergency medicine departments is increasingly being set up in Germany. Staffing, the introduction of a defined curriculum for board-reviewed emergency medicine physicians and identifying specific quality-of-care standards are subject to the current vital discussion. The emergency medicine department plays an essential role in patient triage and initiating early effective therapies for admitted patients with acute and serious conditions. As in trauma care, tools have been developed for the triage of medical patients who might be in need of specific therapy, for example, anti-infective therapy, but there is only little known about the feasibility and effectiveness of specific ABS-programmes targeting antibiotic consumption in emergency departments (ED) by using core ABS tools. However, several studies underscore the demand for such programmes by detecting a rather poor compliance to current infectious disease guidelines in such settings and indicating an overuse of antibiotic substances, notably, broad-spectrum anti-infectives.

Among the most frequently diagnosed and treated infections are community acquired pneumonia (CAP), urinary tract infections (UTI) and skin and soft tissue infections. Regarding the management of acute respiratory infections in the ED, treatment decisions can be facilitated by procalcitonin-guided algorithms. Computerised decision support systems, restrictive strategies aiming at a reduction in ciprofloxacin use and even computer kiosk-expedited management of UTIs have been evaluated with moderate effects on antibiotic prescriptions in the ED. Optimal selection of the targeted antibacterial drugs needs careful review of local resistance, drug use data and strategic decisions that take individual clinical and ecological (collateral damage) aspects into account. Given the trends for more adverse ecological effects of broad-spectrum cephalosporin versus penicillin use, we planned a before-and-after uncontrolled interventional study using interrupted time-series (ITS) analysis in one ED to investigate ABS intervention-related effects in a quasi-experimental research setting aiming at a reduction of third-generation cephalosporin and fluoroquinolone use in medical emergency patients.

**MATERIAL AND METHODS**

**Study design**

Briefly, our study was designed as an ITS to investigate intervention-related effects of ABS programmes in a quasi-experimental research setting. There was no formal calculation on the number of patients needed to include in the study. Antibiotic use data were gathered on a monthly basis from the hospital pharmacy service representing the antibiotic consumption of this clinical department. Written prescriptions handed out for outpatient pharmacies were not included in our study. The number and length of stay of all patients seen in the ED were used to calculate normalised consumption values per 100/patient days. The ethics committee was notified about the trial —formal approval was not required, because the project was based on epidemiological data. Research involving human subjects, human material, specific human or personalised data was not carried out.

**Setting**

Freiburg University Hospital is a 1600-bed academic teaching hospital and tertiary care referral centre, with all major clinical services and departments including renal, lung, heart, haematopoetic stem cell transplant and a level 1 trauma centre. The ED has a 39-bed capacity with four emergency rooms, 10 intermediate care beds equipped with advanced monitoring capabilities and 25 standard care beds. The non-trauma section of the emergency medicine department is operated by three shifts; there are 17 full physician appointments. There are eight on a permanent basis and nine on rotation. During day shifts, there are three internal medicine residents, one internal medicine attending physician and one neurology resident present. During night shifts, there are two internal medicine residents plus one attending physician in service. Each patient is evaluated within 24 h for being admitted or treated on an outpatient basis. In 2013, there were about 38 000 patient contacts in total, 60% trauma patients and 40% medical service patients. Overall, approximately 35% of the patients were admitted for in-hospital treatment. The patients were triaged according to the emergency severity index (ESI). In 2013, 2.5% of the patients were scored as ESI 1, 13% were categorised as ESI 2, 37.5% ESI 3 and 47.5% were assigned to ESI 4 and 5, that is, about 15.5% of all patients required an immediate life-saving intervention or were in a high-risk situation.

**Antibiotic policy and stewardship programme**

Locally consented guidelines for the most frequent indications and acute infections were first available in written formats in 2006. In the following years, the overall hospital-wide antibiotic use density remained stable. However, the use of third-generation cephalosporins and fluoroquinolones increased. Ceftriaxone was one of the most frequently prescribed antibiotic drug and became the first-line drug for treating CAP. Due to increasing rates of enteric bacteria-producing ESBL and vancomycin-resistant enterococci, internal guidelines were revised in October 2011. An intensified ABS programme targeting cephalosporin and fluoroquinolone use on medical wards was initiated and included the medical section of the ED.

The programme included the following components: guideline revision, information, education, intensified infectious disease consultations and standardised treatment protocols. Briefly, we started short-team briefings led by an infectious disease specialist, emphasised the need for infectious disease consultations in the ED by dedicated infectious disease physicians providing academic detailing and feedback. Fluoroquinolone and cephalosporin use, especially the use of third-generation cephalosporins, was discouraged; the use of penicillins was encouraged. The main replacement drug for ceftriaxone was ampicillin/sulbactam. The revised internal guidelines now recommended ampicillin/sulbactam formulations as first-line antibiotics for CAP (the ‘Standard Operating Procedure’ CAP is available from the author on request). Additionally, the use of combination therapy, in particular, including fluoroquinolones, was discouraged. Further, the 2006 established internal infectious disease guidelines covering a broad spectrum of indications were revised and made available in written, pocket-sized formats and accessible on the hospital intranet as well. Our initial idea was to test whether a reduction by >20% in the prescription of both cephalosporins and fluoroquinolones would be possible within 12–24 months, without increasing overall use densities. The number of formal bedside infectious disease emergency consultations remained constant over time, but the number of kerbside and telephone infectious disease consultations increased by 10%
between preintervention and postintervention, and there were many more briefings and interdisciplinary conferences including infectious disease physicians postintervention.

Outcome data
Antibiotic use data were gathered on a monthly basis from the hospital pharmacy service—before (January 2008 to October 2011) and after starting the intervention (November 2011 to October 2013). Antibiotic use density was expressed as WHO-ATC DDD, and doses adapted to local guidelines RDD, normalised per 100 patient (occupied beds) days to account for discrepancies between DDD for penicillins and commonly RDD in hospital practice. Case-mix indices, the number of patient cases and the number of admissions were obtained from the hospital administration.

Statistical analysis
The effect of the intervention on drug use density (in RDD per 100 patient days) was analysed using ITS with the period between January 2008 through October 2011 as preintervention and November 2011 through October 2013 as postintervention periods. Monthly antibiotic use data were used for the analysis. Basically, ITS allows accounting for two effects of the intervention: a level-effect or a slope-effect. As our data indicate a level change (for trend change calculations see online supplementary table S1), our regression model to analyse the use of antibiotic Y over time t in a single setting was specified accordingly:

\[ Y_t = \beta_0 + \beta_1 \times \text{time}_t + \beta_2 \times \text{intervention}_t + u_t. \]

For introduction to the concept of ITS in the context of measuring intervention-related effects in antibiotic consumption we recommend the following references.\textsuperscript{31–34} In detail, \( \beta_0 \) determines the baseline level of the respective antibiotic use in January 2008, \( \beta_1 \) determines the baseline linear trend in the use of the respective antibiotic over the entire study period. \( \beta_2 \) determines the level-effect after the intervention. \( u_t \) represents the error term. All Analyses were carried out using Stata V.12 (StataCorp, College Station, T exas, USA). W e applied linear regressions with Newey–West SE with a maximum lag of 2 to be considered in the autocorrelation structure.

Descriptive statistical analysis of the data in DDD or RDD per 100 patient days was performed by using Microsoft Excel software. Heteroskedastic t test was applied to compare the mean monthly drug use densities before and after the intervention.

RESULTS
The total antibiotic use density decreased in the postintervention period (for overview see figure 2 and table 1). The mean monthly drug use density values preintervention were 111 RDD (138 DDD) per 100 patient days. Following the start of the stewardship programme, these values declined by \(-22\%\), if RDD per 100 patient days was considered \((-7\%\) for DDD/100) (table 1). However, the postinterventional level changes missed statistical significance in the ITS model (95% CI (\(-39.99\) to 0.466)).

As intended and expected, strong effects associated with the intervention were observed for cephalosporins and penicillins. The consumption of third-generation cephalosporins declined substantially (figure 1, table 1) from 34 to 11 RDD/100 (p<0.001), whereas, the use of ampicillin/sulbactam increased almost 10-fold (p<0.001). The ITS confirmed that most of the

<table>
<thead>
<tr>
<th>Drug class</th>
<th>DDD/100</th>
<th></th>
<th>Per cent change</th>
<th>p Value</th>
<th>RDD/100</th>
<th></th>
<th>Per cent change</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cephalosporins</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-</td>
<td>41</td>
<td>31</td>
<td>-24</td>
<td>&lt;0.01</td>
<td>39</td>
<td>22</td>
<td>-42</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Post-</td>
<td>34</td>
<td>11</td>
<td>-68</td>
<td>&lt;0.001</td>
<td>34</td>
<td>11</td>
<td>-68</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Penicillins</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-</td>
<td>19</td>
<td>39</td>
<td>99</td>
<td>&lt;0.001</td>
<td>18</td>
<td>22</td>
<td>22</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Post-</td>
<td>7</td>
<td>20</td>
<td>214</td>
<td>&lt;0.001</td>
<td>4</td>
<td>11</td>
<td>202</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Piperacillin±BLI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-</td>
<td>14</td>
<td>11</td>
<td>-22</td>
<td>&lt;0.001</td>
<td>16</td>
<td>12</td>
<td>-22</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Post-</td>
<td>2</td>
<td>22</td>
<td>835</td>
<td>&lt;0.001</td>
<td>1</td>
<td>8</td>
<td>782</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Aminopenicillins±BLI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-</td>
<td>3</td>
<td>6</td>
<td>74</td>
<td>0.11</td>
<td>1</td>
<td>2</td>
<td>63</td>
<td>0.11</td>
</tr>
<tr>
<td>Post-</td>
<td>6</td>
<td>3</td>
<td>-47</td>
<td>&lt;0.001</td>
<td>4</td>
<td>2</td>
<td>-49</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fluroquinolones</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-</td>
<td>21</td>
<td>17</td>
<td>-22</td>
<td>&lt;0.05</td>
<td>19</td>
<td>14</td>
<td>-26</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Post-</td>
<td>2</td>
<td>22</td>
<td>835</td>
<td>&lt;0.001</td>
<td>1</td>
<td>8</td>
<td>782</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Aminoglycosides</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-</td>
<td>0.5</td>
<td>0.3</td>
<td>-31</td>
<td>0.34</td>
<td>0.4</td>
<td>0.2</td>
<td>-31</td>
<td>0.34</td>
</tr>
<tr>
<td>Post-</td>
<td>2</td>
<td>1</td>
<td>-67</td>
<td>&lt;0.001</td>
<td>2</td>
<td>1</td>
<td>-67</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Glycopeptides</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-</td>
<td>40</td>
<td>32</td>
<td>-20</td>
<td>&lt;0.05</td>
<td>22</td>
<td>19</td>
<td>-12</td>
<td>0.22</td>
</tr>
<tr>
<td>Post-</td>
<td>40</td>
<td>32</td>
<td>-20</td>
<td>&lt;0.05</td>
<td>22</td>
<td>19</td>
<td>-12</td>
<td>0.22</td>
</tr>
<tr>
<td>Macrolides/Clindamycin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-</td>
<td>40</td>
<td>32</td>
<td>-20</td>
<td>&lt;0.05</td>
<td>22</td>
<td>19</td>
<td>-12</td>
<td>0.22</td>
</tr>
<tr>
<td>Post-</td>
<td>40</td>
<td>32</td>
<td>-20</td>
<td>&lt;0.05</td>
<td>22</td>
<td>19</td>
<td>-12</td>
<td>0.22</td>
</tr>
<tr>
<td>Total</td>
<td>138</td>
<td>128</td>
<td>-7</td>
<td>0.24</td>
<td>111</td>
<td>86</td>
<td>-23</td>
<td>0.001</td>
</tr>
</tbody>
</table>

BLI, β-lactamase inhibitor; DDD, defined daily doses; RDD, recommended daily doses.
Figure 2  Run-charts for all anti-infective substances.
decline of third-generation cephalosporins was, in fact, attributable to the intervention (table 2) with an intervention-related decrease of 15.2 RDD/100 (95% CI (−24.08 to −6.31)). By contrast with third-generation cephalosporins, other cephalosporins were increasingly prescribed following the intervention. The mean monthly use density values for first-generation and second-generation cephalosporins increased twofold, and this increase was almost entirely associated with the intervention (table 2).

There was no negative impact of the intervention in terms of increasing use of broad-spectrum betalactams (piperacillin/tazobactam and carbapenems), fluoroquinolones or aminoglycosides (table 1, figure 2). The consumption of piperacillin/tazobactam and/or carbapenems showed a decreasing rather than increasing level effect postintervention. Fluoroquinolone use density declined over the observation period (>20%), the level change between preintervention and postintervention for fluoroquinolone use did not reach statistical significance (95% CI (−11.72 to 4.333)).

**DISCUSSION**

We demonstrated that an intensified ABS programme targeting third-generation cephalosporin and fluoroquinolone use in the setting of a large academic hospital ED is feasible and effective. ITS confirmed a highly significant postintervention level change of third-generation cephalosporins and a corresponding increase in the use of aminopenicillin/betalactamase inhibitor formulations. The drug use densities for fluoroquinolones and for overall antibiotics declined, however, both results missed statistical significance. ITS analysis is the statistic tool of choice to investigate intervention-related effects of ABS programmes in a quasi-experimental research setting.19

Our programme was focused on medical service patients including the ED, which is the interface between outpatient and in-hospital care and is, therefore, highly relevant for acute therapeutic decisions, including drug choices in acute infections. We were interested in demonstrating the success of our programme in the ED, since we considered its effect to be essential for having a strong impact on the consumption in other medical service areas of this hospital. The programme itself used established components and tools of ABS interventions, such as revision, consensus and dissemination of local guidelines, education and feedback with discussion. Due to continuing efforts, we achieved sustainability over 2 years, however, changes in hospital-wide resistance patterns and data on possible changes in the incidence of nosocomial infections are not yet available; this is a major limitation of the study. It will be important to evaluate these outcome data ‘medical service-wide’, since the relatively short length of stay in the ED, the time elapsing between antibiotic therapy initiation and selection of a nosocomial superinfection with resistant micro-organisms makes it difficult to show a within-department impact on such endpoints. The present study is another example for the feasibility of ABS interventions in acute care hospitals, even in the setting of a ‘high throughput’ department. Many previous studies have focused on reduced cephalosporin and fluoroquinolone prescriptions and have shown variable results regarding overall consumption, effects on bacterial resistance and *C difficile* infections.10 11 It remains unknown how large, radical and how sustained the reduction of cephalosporins needs to be in order to exert durable effects on bacterial resistance and *C difficile* infections. Further, it is worth to speculate, which of the ‘replacement’ drug classes are optimal or rather negatively interfere with potential positive ecological effects in ABS programmes that successfully reduce cephalosporin prescriptions. We believe that more experience, with targeted ABS programmes

**Table 2: Results of an interrupted time-series analysis comparing preintervention and postintervention use of selected antibacterial drug classes in medical emergency patients (n=46)**

<table>
<thead>
<tr>
<th>Group</th>
<th>Baseline trend</th>
<th>Postintervention increase</th>
<th>Constant</th>
<th>N</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>1G</td>
<td>0.0509</td>
<td>−0.174</td>
<td>0.0447</td>
<td>70</td>
<td>0.0001</td>
</tr>
<tr>
<td>2G</td>
<td>−0.218</td>
<td>−0.659</td>
<td>0.007</td>
<td>70</td>
<td>0.0162</td>
</tr>
<tr>
<td>3G</td>
<td>0.931†</td>
<td>1.617</td>
<td>0.0017</td>
<td>70</td>
<td>0.0282</td>
</tr>
<tr>
<td>CEPH</td>
<td>−2.906</td>
<td>0.0324</td>
<td>0.0107</td>
<td>70</td>
<td>0.0015</td>
</tr>
<tr>
<td>AMINOBLU</td>
<td>1.407</td>
<td>0.448</td>
<td>0.0559</td>
<td>70</td>
<td>0.0003</td>
</tr>
</tbody>
</table>

%5G, GC, generation of cephalosporins; 3G, third-generation cephalosporins; RDD, recommended daily doses.

**Table 2: Results of an interrupted time-series analysis comparing preintervention and postintervention use of selected antibacterial drug classes in medical emergency patients (n=46)**

<table>
<thead>
<tr>
<th>Group</th>
<th>Baseline trend</th>
<th>Postintervention increase</th>
<th>Constant</th>
<th>N</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>1G</td>
<td>0.0509</td>
<td>−0.174</td>
<td>0.0447</td>
<td>70</td>
<td>0.0001</td>
</tr>
<tr>
<td>2G</td>
<td>−0.218</td>
<td>−0.659</td>
<td>0.007</td>
<td>70</td>
<td>0.0162</td>
</tr>
<tr>
<td>3G</td>
<td>0.931†</td>
<td>1.617</td>
<td>0.0017</td>
<td>70</td>
<td>0.0282</td>
</tr>
<tr>
<td>CEPH</td>
<td>−2.906</td>
<td>0.0324</td>
<td>0.0107</td>
<td>70</td>
<td>0.0015</td>
</tr>
<tr>
<td>AMINOBLU</td>
<td>1.407</td>
<td>0.448</td>
<td>0.0559</td>
<td>70</td>
<td>0.0003</td>
</tr>
</tbody>
</table>

%5G, GC, generation of cephalosporins; 3G, third-generation cephalosporins; RDD, recommended daily doses.
and controlled before-and-after studies is needed to address these
questions properly.

Our study has several limitations. We did not use a control
department against which the observed trend changes could be
Evaluated, and it cannot be excluded that there were some unrel-
ated changes occurring independent from the intervention.
Internal controls were unavailable, due to the unique nature of a
single ED at this hospital and its influence on the prescribing
on wards to which the patients were admitted. Second, although
case-mix indices remained similar throughout the observation
period, we cannot be sure that disease severity and the distribu-
tion of admission diagnoses remained unchanged over time.
Third, we did not systematically follow-up individual patients
and, therefore, cannot provide data confirming similar patient
outcomes preintervention and postintervention, or data regarding
intervention adherence and prescription quality. In an anal-
ysis of medical service-wide data from January 2008 to March
2013, we documented unchanged case-mix indices, discharge
statistics, including in-hospital mortality and time-to-discharge,
respectively, with length-of-hospital-stay.57 From March 2013 to
October 2013, these crude outcome estimates remained, fur-
thermore, roughly unchanged. We, therefore, believe that
adverse outcomes of our intervention are very unlikely, although
there are no specific data available on the ED level.

We were somehow surprised to see a decreasing use of carba-
penems and broad spectrum pencillins (BSPs) (piperacillin/tazo-
bactam), with significant postinterventional level changes in
the ITS. These drug classes were not primary target drugs of our
intervention. We hypothesise that the decreasing use density of
this non-target drug classes were the results of facilitated general
discussions and ward rounds with dedicated infectious disease
consultants. We used persuasive rather than restrictive tools to
alter the antibiotic policy in the department and were able to
achieve our pursued reduction of cephalosporins and fluoroqui-
nolones by >20%, however, the level change of fluoroquino-
lone prescriptions was not significant.

Of note, a small trend of fewer fluoroquinolone prescriptions
was already observed prior to the programme initiation. This
trend might, in part, have been related to a decision taken early
in 2011 to abandon fluoroquinolone prophylaxis in haematology-ontology patients and was then intensified by reducing combination therapies including fluoroquinolones postintervention. We speculate, that fluoroquinolone consumption has reached a baseline usage in the framework of unaltered postintervention. We speculate, that reducing combination therapies including


Robinson HL, Robinson PC, Whitby M. Poor Compliance with Community-Acquired Pneumonia Antibiotic Guidelines in a Large Australian Private Hospital Emergency
Implementation of an intensified antibiotic stewardship programme targeting third-generation cephalosporin and fluoroquinolone use in an emergency medicine department

Johannes P Borde, Winfried V Kern, Martin Hug, Michaela Steib-Bauert, Katja de With, Hans-Jörg Busch and Klaus Kaier

Emerg Med J 2015 32: 509-515 originally published online September 26, 2014
doi: 10.1136/emermed-2014-204067

Updated information and services can be found at:
http://emj.bmj.com/content/32/7/509

These include:

Supplementary Material
Supplementary material can be found at:
http://emj.bmj.com/content/suppl/2014/09/22/emermed-2014-204067.DC1

References
This article cites 31 articles, 7 of which you can access for free at:
http://emj.bmj.com/content/32/7/509#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Editor's choice (122)
Drugs: infectious diseases (287)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/